A Phase I Study of Atezolizumab (MPDL3280A) Immunotherapy in Children and Young Adults with Persistent Solid Tumors

Full Title

An Early Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolixumab (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors (GO29664).


The purpose of this study is to evaluate certain doses of the immunotherapy drug atezolizumab (also called MPDL3280A) in children and young adults with solid tumors that continue to grow despite prior therapy. Atezolizumab is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating bladder cancer; its use in this study is considered investigational. Atezolizumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is for patients under age 30.
  • Patients must have tumors that continue to grow despite prior treatment and produce PD-L1. Examples include certain soft-tissue sarcomas, osteosarcomas, Hodgkin lymphomas, non-Hodgkin lymphomas, neuroblastoma, and Wilms’ tumors.
  • Patients should recover from the serious side effects of prior therapies before entering the study.

For more information about this study and to inquire about eligibility, please contact Dr. Tanya Trippett at 212-639-8267.





Disease Status

Relapsed or Refractory